As patients pay more for their medicines out-of-pocket, PBMs and insurers benefit from rebates and discounts that lower their prices for those same medicines, according to a recent report from the Bureau of Economic Analysis.
In fact, the report shows that the prices insurers make patients pay out-of-pocket for their medicines has steadily increased since 2016. The growth in patients’ out-of-pocket prices far outpaced growth in the prices insurers faced for those medicines during the same time period.
Price indexes are normalized to 100 in 2007
These data provide yet another example of the growing gap between what insurers pay for medicines and what they decide patients must pay out-of-pocket.
As the report found, concerns about the cost of prescription drugs, “align more closely with the persistent increase in out-of-pocket prices than the recently stagnating growth of negotiated prices.”
It also makes clear that rising out-of-pocket prices are likely to disproportionately impact lower-income individuals and patients with chronic disease.
Patients pay more, insurers pay less.
Insurers and PBMs often receive significant rebates and discounts that lower what they pay for medicines, yet often refuse to pass those savings directly to patients to lower what they pay at the pharmacy.
Instead, insurers are shifting more costs to patients through deductibles and coinsurance, which are often based on the list price of a medicine, not the lower net price insurers and PBMs pay.
When middlemen prevent savings from going to patients, they pay less as patients pay more. In fact, some patients can pay more for their medicines than their insurer or PBM did.
Savings should go to patients, not middlemen.
Congress has an opportunity to enact reforms to realign incentives in the market and stop middlemen, like PBMs and insurers, from profiting at the expense of patients.
Policymakers can pass reforms that require insurers and PBMs to pass savings directly to patients to lower their costs at the pharmacy and prohibit middlemen from profiting based on the list prices of drugs.
If policymakers want to increase access and lower the cost of prescription drugs, they should address the PBM middlemen in the system who are unfairly driving up the cost of medicines.
Nick McGee
Nick McGee is deputy vice president, public affairs, at PhRMA focusing on communications strategies and activities for the organization’s advocacy priorities.
Nick McGee
What AARP isn’t telling seniors about MFN
Policymakers should improve patient access and reject price controls
Insurers blame GLP-1s for rising costs. The data tells a different story.
The FTC’s PBM enforcement actions gave us a glimpse behind the curtain; it’s time to let the light in.
Nearly 1 in 4 patients initially denied access to IRA medicines
Message to USAging: Providers are raising concerns about coverage barriers
New PBM principles don't change the fundamental challenge: Access to lower-cost medicines
340B’s reality: A booming business for hospitals, pharmacies and corporate giants
Insurers are blaming medicines for premium hikes in Massachusetts. The state's own data suggests otherwise.
Briefing: Capitol Hill panel on "Healthcare Denial Crisis in America"
Survey confirms too many insured Americans face barriers to reliable health care
70% DENIED: How insurance denials are delaying and preventing care for millions of Americans
Hospitals drive nearly 80% of the U.S. health spending gap
No hassle, hidden markups or fees: AmericasMedicines.com
The Federal Trade Commission (FTC) takes important action to highlight and curb PBM abuses
Separating fact from fiction in the medicine supply chain
50-state poll says Americans are concerned that hospital markups hurt patients
Three things you should know from the insurer CEO congressional hearings
Can’t get your medicine? Don’t count on your insurer.
Stop, collaborate and re-evaluate: ICER’s pricing report
California’s landmark PBM crackdown: A wake-up call for reform
Middlemen mark up drug prices and keep discounts meant for you
Putting patients first: Breaking down barriers to care
Direct purchase programs can lower costs for patients
PBMs say they want lower priced medicines, so why don’t they cover them?
Historic biopharmaceutical investments: A prescription for America’s future
Why states struggle to deliver savings: Middlemen and 340B siphon dollars from patients and states
PBMs are hiding hurdles to essential care
New study: PBMs and commercial insurers are quietly blocking prescription access
North Carolina puts patients first with rebate pass-through law
PBMs, not patents, are blocking access to lower-cost medicines
Medicare Part D plans initially denied medicines for more than 70% of patients in four chronic disease areas
New “Balance the Scales” campaign highlights why Americans pay more for prescription medicines
How the 340B hospital markup program and PBMs drive up costs for U.S. patients
Foreign first pricing schemes don’t address why Americans pay more
The AHIP premium dollar corrected (again)
PBMs launch new ad campaign to block reforms
When middlemen own it all, patients pay the price
3 myths critics get wrong about intellectual property
New report finds more abuse of 340B program by hospitals and drug middlemen
A closer look at how health care consolidation drives up patient costs, creates barriers to care
Health care practitioners sound the alarm on middlemen-imposed barriers to patient care, need for policy change
Congress Keeps PBMs in the Hot Seat
Wrapping up the J.P. Morgan Healthcare Conference
FTC finds PBMs make billions in profit from marking up cancer, other critical generic drugs
PhRMA CEOs Tee Up Next Week's Health Care Conference
New study: Entities that don’t make medicines get half of what is spent on those medicines
Three things to know about 340B contract pharmacies
The PBM industry's desperate attempt to stop reform
PhRMA launches new ad calling for Congress to make sure savings go to patients, not PBMs
ICYMI: Grounding policy reforms in real lived patient experiences is key to improving outcomes
New PES survey: Out-of-pocket costs lead key health care priorities ahead of the November election
Guest Post: My health care vote
Americans speak out on health insurance barriers and need for policy change, according to the latest Patient Experience Survey
ICYMI: The powerful companies driving local drugstores out of business
Hispanic Heritage Month: Fighting for Hispanic patients
PBMs and insurers off the hook: Sen. Sanders’ selective hearing on drug costs
Key voter insights two months from Election Day
Patient priorities in the 2024 election
Voters across all 50 states want state policymakers to focus on health insurance and PBM practices
WTAS: Voters voice concerns about PBM abuses, call on policymakers to act
PhRMA launches new ad in campaign exposing ways middlemen drive up costs
FTC report confirms PBMs profit at the expense of patients
New 50-state poll Americans want to hold health insurers and PBMs accountable for high out-of-pocket costs and other practices
ICYMI: Hidden markups at mail-order pharmacies increase costs for employers
ICYMI: What patients care about this election year
ICYMI: The Opaque Industry Secretly Inflating Prices for Prescription Drugs
ICYMI: Health care policy should be driven by patients, not politics
PhRMA Warns Federal Agencies: Consolidation and vertical integration among insurers, PBMs, and hospitals threaten patients
ICYMI: Innovation transforms lives but misguided federal policies threaten patient outcomes
Ongoing federal probes shed light on PBM and insurer practices
WTAS: The consequences of consolidation and vertical integration
Insurance data: PBM reform has no material impact on premiums
New study finds insurers and PBMs increasing access restrictions in Medicare Part D
3 Takeaways from POLITICO’s Health Care Summit
PBMs using 340B program to drive profits at patients’ expense
Four years later, Maryland board still hasn’t delivered for patients
How the 340B program became a PBM giveaway
ICYMI: When middlemen get in the way, it’s the patients who lose
Get the facts on PCMA’s newest attempt to avoid accountability
ICYMI: WSJ — Same Drug, Two Prices: Why the Higher Price Prevails
ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference
One year to Election Day: Four voter priorities to watch
ICYMI: Scott LaGanga and Matt Salo deliver a State of the Industry Report
New poll shows strong bipartisan support for PBM reform
4 truths about state government price setting
ICYMI: Government watchdog report finds patients in Medicare Part D paid billions more for medicines than insurers and PBMs
New analysis shows PBMs use fees as a profit center
It’s PBMs, not patents, blocking competition
New PhRMA ad exposes yet another way PBMs get between patients and their medicines
Navigating the Patient Experience Survey: Protecting Lifelines to Access and Innovation
Three things to know from the latest Patient Experience Survey
ICYMI: PBM exec admits choosing profits over patients
Insulin: Key Facts on Access & Affordability
4 key facts on medicine prices and spending
4 Things to know about PhRMA’s new 50-state poll
New PhRMA ad campaign sheds light on PBM abuses
Three facts about health care spending
AHIP’s latest misinformation campaign & what it’s trying to hide
ICYMI: PhRMA President and CEO Stephen J. Ubl discusses patient affordability
States can support access to medicine as COVID-19 Public Health Emergency ends
Arkansas puts patients first with new share the savings law
Key Trends: Patient experience data reveal how insurers and middlemen impose barriers in health care
Insurer and PBM tactics are shifting higher costs to patients with chronic and complex conditions
Holding pharmacy benefit managers accountable
Stopping pharmacy benefit managers from “gaming the system”
Senate hearing to examine bipartisan reforms to rein in middlemen
Minnesota lawmakers are letting PBMs off the hook, and threatening patients’ access to medicines
ICYMI: PhRMA COO Lori Reilly speaks about the health care agenda for the next Congress
In their own words: Financial barriers exacerbate access challenges for insured Americans
New data show how insurers and middlemen shift Rx costs onto patients
In their own words: Insured Americans struggle to navigate complex coverage
New comments outline ways to protect patients from health plans and PBMs who profit from patient assistance
Navigating the patient experience: Burdens and barriers standing between patients and their care
Insulin and reconciliation
Patients win as West Virginia implements first-in-nation share the savings policy
3 things voters are concerned about when it comes to their health care coverage
Patients support state action requiring PBMs and insurers to share savings and cap costs for medicines
New poll shows voters sounding the alarm on health insurance companies and PBMs
PhRMA warns of the growing influence of middlemen over patient access and out-of-pocket costs for patients
Government price setting won’t stop insurers from shifting costs to patients
New insulin report highlights how incentives benefit middlemen, harm patients
Key facts: The final rebate rule will be a positive change for patients
PhRMA submits comments on ways to refocus the 340B program on America’s vulnerable patients
Study finds middlemen excluded nearly 850 medicines from formularies this year
PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs
340B Spotlight: How for-profit middlemen are taking advantage of a program meant to support nonprofit entities and patients
Five key facts about the market for insulins
The PBM story you haven’t heard: Hidden fees quadrupled in two years
OptumRX: Sharing rebates with patients is “worth it”
Event tomorrow: Making the biopharmaceutical supply chain work for patients
Advance price notification: A transparency measure that fails patients
New Let’s Talk About Cost ads highlight how copay accumulator programs could leave patients financially exposed
ICYMI: Two PBM reports show dramatic slowdown in medicine spending growth
Copay coupons can help ease patients’ out-of-pocket costs
Why won’t the insurance industry tell the truth about medicine costs?
Insurers continue shifting more costs on to patients
PBMs/Insurance
Insurers continue shifting more costs on to patients
Insurers continue shifting more costs on to patients